Aeglea BioTherapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held June 8, 2020
May 28 2020 - 4:10PM
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage
biotechnology company developing a new generation of human enzyme
therapeutics as innovative solutions for rare and other high-burden
diseases, today announced that, due to the public health impact of
the coronavirus (COVID-19) pandemic, the location of the Company’s
2020 annual meeting of stockholders has been changed and will be
held in a virtual meeting format only. As previously announced, the
annual meeting will be held on Monday, June 8,
2020 at 9:00 a.m. Central Time. To be admitted to the
annual meeting at www.virtualshareholdermeeting.com/AGLE2020,
stockholders must enter the control number found on their proxy
card, voting instruction form or notice previously received.
Further information regarding this change to the location of the
annual meeting can be found in the supplemental proxy materials
filed by Aeglea with the Securities and Exchange
Commission on May 28, 2020.
About Agelea BioTherapeutics,
Inc.
Aeglea BioTherapeutics is a clinical-stage
biotechnology company redefining the potential of human enzyme
therapeutics to benefit people with rare and other high burden
diseases. Aeglea's lead product candidate, pegzilarginase, is in a
pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency
and has received both Rare Pediatric Disease and Breakthrough
Therapy Designations. The Company received approval of its Clinical
Trial Application (CTA) for ACN00177 for the treatment of
Homocystinuria by the United Kingdom’s Medicines and
Healthcare Products Regulatory Agency (MHRA). Aeglea has an
active discovery platform, with the most advanced program for
Cystinuria. For more information, please
visit http://aegleabio.com.
Safe Harbor / Forward Looking
Statements
This press release contains "forward-looking"
statements within the meaning of the safe harbor provisions of
the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such
as: "anticipate," "intend," "plan," "goal," "seek," "believe,"
"project," "estimate," "expect," "strategy," "future," "likely,"
"may," "should," "will" and similar references to future periods.
These statements are subject to numerous risks and uncertainties
that could cause actual results to differ materially from what we
expect. Examples of forward-looking statements include, among
others, statements we make regarding our plans to hold the 2020
annual meeting of stockholders. Further information on potential
risk factors that could affect our business and its financial
results are detailed in our most recent Quarterly Report on Form
10-Q for the quarter ended March 31, 2020 filed with
the Securities and Exchange Commission (SEC), and other
reports as filed with the SEC. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Media Contact:Kelly Boothe,
Ph.D.Director, Corporate CommunicationsAeglea
BioTherapeutics512.399.5458media@aegleabio.com
Investor Contact:Joey
PerroneSenior Director, Finance & Investor RelationsAeglea
BioTherapeuticsinvestors@aegleabio.com
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Apr 2023 to Apr 2024